Company |
Company |
Deal value |
Foundation Medicine Inc. (Cambridge, Mass.) |
Roche AG (Basel, Switzerland) |
$1.05B |
Depomed Inc. (Newark, Calif.) |
Janssen Pharmaceuticals Inc. (New Brunswick, N.J.) |
$1.005B |
Isis Pharmaceuticals Inc. (Carlsbad, Calif.) |
Janssen Biotech Inc. (New Brunswick, N.J.) |
$835M |
AC Immune SA (Geneva) |
Janssen Pharmaceuticals (New Brunswick, N.J.) |
$509M |
NGM Biopharmaceuticals Inc. (South San Francisco) |
Merck & Co. Inc. (Whitehouse Station, N.J.) |
$450M |
Pfenex Inc. (San Diego) |
Hospira Inc. (Lake Forest, Ill.) |
$341M |
Rigel Pharmaceuticals Inc. (South San Francisco) |
Bristol-Myers Squibb Co. (New York) |
$339M |
Aegerion Pharmaceuticals Inc. (Cambridge, Mass.) |
Astrazeneca plc (London) |
$325M |
Theravance Biopharma Inc. (South San Francisco) |
Mylan Inc. (Pittsburgh) |
$265M |
Vedanta Biosciences Inc. (Boston) |
Janssen Biotech Inc. (New Brunswick, N.J.) |
$241M |